"Digital divide" between old and young docs narrowing, survey finds

Share this article:
Three out of five doctors are now using technology to better communicate with patients, a MedPage Today survey has found, and two-fifths say patients are generally more informed than they were five years ago.

The physician portal's Today's Physician: Managing Change survey of 214 physicians found surprisingly little variance by age in physician usage of technology – those 56 and up were somewhat more likely to use a computer in their medical practice (90%, versus 86% of those under 56), and less likely to use a smartphone (three in five of the over 56 doctors did, where four out of five younger physicians did. Usage of handheld devices was about even (45% for 56+, 46% for younger docs). The top reason for docs using the Internet and mobile devices is for medical news, the survey found, and 80% feel that technology has improved their communication with patients.

Physicians surveyed expressed anxiety about the sea changes sweeping the health industry in the wake of the Affordable Care Act's passage and validation by the Supreme Court. Nearly half (48%) said they expect to see a change in governance of their practice over the next five years, and 9% said they think their practice will go out of business. It won't come as any surprise to drug company execs that they find they have less time to spend with patients, to say nothing of continuing education, attending conferences, reading journals and meeting with reps.  
 
Anthony Manson, VP sales development at MedPage Today parent Everyday Health, said: “From a pharma marketing standpoint, the question is: Have we adjusted our marketing plans to reflect the new environment? Have we adjusted our media mix? Are we thinking about how to provide more value and more support to the physicians as they go through these difficult times? And is pharma really leveraging all the new contact channels? A lot of brand.coms are still not mobile-enabled.”
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.